{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,12]],"date-time":"2026-06-12T20:20:51Z","timestamp":1781295651917,"version":"3.54.1"},"reference-count":50,"publisher":"Elsevier BV","issue":"12","license":[{"start":{"date-parts":[[2021,3,1]],"date-time":"2021-03-01T00:00:00Z","timestamp":1614556800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,3,1]],"date-time":"2021-03-01T00:00:00Z","timestamp":1614556800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,3,1]],"date-time":"2021-03-01T00:00:00Z","timestamp":1614556800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2021,3,1]],"date-time":"2021-03-01T00:00:00Z","timestamp":1614556800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2021,3,1]],"date-time":"2021-03-01T00:00:00Z","timestamp":1614556800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2021,3,1]],"date-time":"2021-03-01T00:00:00Z","timestamp":1614556800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2021,3,1]],"date-time":"2021-03-01T00:00:00Z","timestamp":1614556800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100000060","name":"National Institute of Allergy and Infectious Diseases","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000050","name":"National Heart, Lung, and Blood Institute","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000050","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2021,3]]},"DOI":"10.1016\/j.vaccine.2021.01.071","type":"journal-article","created":{"date-parts":[[2021,2,23]],"date-time":"2021-02-23T05:14:19Z","timestamp":1614057259000},"page":"1780-1787","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":15,"title":["Intranasal boosting with MVA encoding secreted mycobacterial proteins Ag85A and ESAT-6 generates strong pulmonary immune responses and protection against M. tuberculosis in mice given BCG as neonates"],"prefix":"10.1016","volume":"39","author":[{"given":"Mayank","family":"Khanna","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hamada","family":"Rady","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guixiang","family":"Dai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alistair J.","family":"Ramsay","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.vaccine.2021.01.071_b0005","unstructured":"WHO, Global tuberculosis report; 2019, World Health Organization, Geneva."},{"issue":"9","key":"10.1016\/j.vaccine.2021.01.071_b0010","doi-asserted-by":"crossref","first-page":"698","DOI":"10.1001\/jama.1994.03510330076038","article-title":"Efficacy of BCG vaccine in the prevention of tuberculosis. Meta-analysis of the published literature","volume":"271","author":"Colditz","year":"1994","journal-title":"Jama"},{"issue":"9517","key":"10.1016\/j.vaccine.2021.01.071_b0015","doi-asserted-by":"crossref","first-page":"1173","DOI":"10.1016\/S0140-6736(06)68507-3","article-title":"Effect of BCG vaccination on childhood tuberculous meningitis and miliary tuberculosis worldwide: a meta-analysis and assessment of cost-effectiveness","volume":"367","author":"Trunz","year":"2006","journal-title":"Lancet"},{"issue":"2","key":"10.1016\/j.vaccine.2021.01.071_b0020","doi-asserted-by":"crossref","first-page":"e035595","DOI":"10.1136\/bmjopen-2019-035595","article-title":"Neonatal BCG vaccination and child survival in TB-exposed and TB-unexposed children: a prospective cohort study","volume":"10","author":"Thysen","year":"2020","journal-title":"BMJ Open"},{"issue":"9493","key":"10.1016\/j.vaccine.2021.01.071_b0025","doi-asserted-by":"crossref","first-page":"1290","DOI":"10.1016\/S0140-6736(05)67145-0","article-title":"Effect of BCG revaccination on incidence of tuberculosis in school-aged children in Brazil: the BCG-REVAC cluster-randomised trial","volume":"366","author":"Rodrigues","year":"2005","journal-title":"Lancet"},{"issue":"2","key":"10.1016\/j.vaccine.2021.01.071_b0030","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1056\/NEJMoa1714021","article-title":"Prevention of M. tuberculosis Infection with H4:IC31 vaccine or BCG Revaccination","volume":"379","author":"Nemes","year":"2018","journal-title":"N Engl J Med"},{"issue":"10","key":"10.1016\/j.vaccine.2021.01.071_b0035","doi-asserted-by":"crossref","first-page":"e1052","DOI":"10.1371\/journal.pone.0001052","article-title":"Boosting BCG with recombinant modified vaccinia ankara expressing antigen 85A: different boosting intervals and implications for efficacy trials","volume":"2","author":"Pathan","year":"2007","journal-title":"PLoS ONE"},{"issue":"11","key":"10.1016\/j.vaccine.2021.01.071_b0040","doi-asserted-by":"crossref","first-page":"1240","DOI":"10.1038\/nm1128","article-title":"Recombinant modified vaccinia virus Ankara expressing antigen 85A boosts BCG-primed and naturally acquired antimycobacterial immunity in humans","volume":"10","author":"McShane","year":"2004","journal-title":"Nat Med"},{"issue":"6","key":"10.1016\/j.vaccine.2021.01.071_b0045","doi-asserted-by":"crossref","first-page":"3814","DOI":"10.1128\/IAI.73.6.3814-3816.2005","article-title":"Boosting with poxviruses enhances Mycobacterium bovis BCG efficacy against tuberculosis in guinea pigs","volume":"73","author":"Williams","year":"2005","journal-title":"Infect Immun"},{"issue":"9871","key":"10.1016\/j.vaccine.2021.01.071_b0050","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.1016\/S0140-6736(13)60177-4","article-title":"Safety and efficacy of MVA85A, a new tuberculosis vaccine, in infants previously vaccinated with BCG: a randomised, placebo-controlled phase 2b trial","volume":"381","author":"Tameris","year":"2013","journal-title":"The Lancet"},{"issue":"12","key":"10.1016\/j.vaccine.2021.01.071_b0055","doi-asserted-by":"crossref","first-page":"1832","DOI":"10.1093\/infdis\/jir195","article-title":"Dose-finding study of the novel tuberculosis vaccine, MVA85A, in healthy BCG-vaccinated infants","volume":"203","author":"Scriba","year":"2011","journal-title":"J Infect Dis"},{"issue":"2","key":"10.1016\/j.vaccine.2021.01.071_b0060","doi-asserted-by":"crossref","first-page":"e87340","DOI":"10.1371\/journal.pone.0087340","article-title":"The candidate TB vaccine, MVA85A, induces highly durable Th1 responses","volume":"9","author":"Tameris","year":"2014","journal-title":"PLoS ONE"},{"issue":"10","key":"10.1016\/j.vaccine.2021.01.071_b0065","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1016\/S1473-3099(14)70845-X","article-title":"Safety and immunogenicity of a candidate tuberculosis vaccine MVA85A delivered by aerosol in BCG-vaccinated healthy adults: a phase 1, double-blind, randomised controlled trial","volume":"14","author":"Satti","year":"2014","journal-title":"Lancet Infect Dis"},{"issue":"4","key":"10.1016\/j.vaccine.2021.01.071_b0070","doi-asserted-by":"crossref","first-page":"e1002790","DOI":"10.1371\/journal.pmed.1002790","article-title":"Alternate aerosol and systemic immunisation with a recombinant viral vector for tuberculosis, MVA85A: A phase I randomised controlled trial","volume":"16","author":"Manjaly Thomas","year":"2019","journal-title":"PLoS Med"},{"issue":"3","key":"10.1016\/j.vaccine.2021.01.071_b0075","doi-asserted-by":"crossref","first-page":"1602","DOI":"10.4049\/jimmunol.171.3.1602","article-title":"Enhanced immunogenicity and protective efficacy against Mycobacterium tuberculosis of bacille Calmette-Guerin vaccine using mucosal administration and boosting with a recombinant modified vaccinia virus Ankara","volume":"171","author":"Goonetilleke","year":"2003","journal-title":"J Immunol"},{"issue":"48","key":"10.1016\/j.vaccine.2021.01.071_b0080","doi-asserted-by":"crossref","first-page":"6800","DOI":"10.1016\/j.vaccine.2015.10.017","article-title":"Improvement of BCG protective efficacy with a novel chimpanzee adenovirus and a modified vaccinia Ankara virus both expressing Ag85A","volume":"33","author":"Stylianou","year":"2015","journal-title":"Vaccine"},{"issue":"8","key":"10.1016\/j.vaccine.2021.01.071_b0085","doi-asserted-by":"crossref","first-page":"e0136635","DOI":"10.1371\/journal.pone.0136635","article-title":"DNA-Launched Alphavirus Replicons Encoding a Fusion of Mycobacterial Antigens Acr and Ag85B Are Immunogenic and Protective in a Murine Model of TB Infection","volume":"10","author":"Dalmia","year":"2015","journal-title":"PLoS ONE"},{"issue":"17","key":"10.1016\/j.vaccine.2021.01.071_b0090","doi-asserted-by":"crossref","first-page":"2768","DOI":"10.1016\/j.vaccine.2012.02.020","article-title":"CD40 Ligand enhances immunogenicity of vector-based vaccines in immunocompetent and CD4+ T cell deficient individuals","volume":"30","author":"Auten","year":"2012","journal-title":"Vaccine"},{"issue":"2","key":"10.1016\/j.vaccine.2021.01.071_b0095","doi-asserted-by":"crossref","first-page":"e0148701","DOI":"10.1371\/journal.pone.0148701","article-title":"Flagellin encoded in gene-based vector vaccines is a route-dependent immune adjuvant","volume":"11","author":"Rady","year":"2016","journal-title":"PLoS ONE"},{"issue":"50","key":"10.1016\/j.vaccine.2021.01.071_b0100","doi-asserted-by":"crossref","first-page":"6267","DOI":"10.1016\/j.vaccine.2016.10.065","article-title":"Gene-based neonatal immune priming potentiates a mucosal adenoviral vaccine encoding mycobacterial Ag85B","volume":"34","author":"Dai","year":"2016","journal-title":"Vaccine"},{"issue":"4","key":"10.1016\/j.vaccine.2021.01.071_b0105","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1080\/14760584.2019.1585246","article-title":"Deciphering protective immunity against tuberculosis: implications for vaccine development","volume":"18","author":"Counoupas","year":"2019","journal-title":"Expert Rev Vaccines"},{"key":"10.1016\/j.vaccine.2021.01.071_b0110","doi-asserted-by":"crossref","first-page":"5.13.1","DOI":"10.1002\/cpps.33","article-title":"Generation of recombinant vaccinia viruses","volume":"89","author":"Wyatt","year":"2017","journal-title":"Curr Protoc Protein Sci"},{"issue":"1","key":"10.1016\/j.vaccine.2021.01.071_b0115","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1128\/IAI.71.1.483-493.2003","article-title":"Mapping of murine Th1 helper T-Cell epitopes of mycolyl transferases Ag85A, Ag85B, and Ag85C from Mycobacterium tuberculosis","volume":"71","author":"D'Souza","year":"2003","journal-title":"Infect Immun"},{"issue":"8","key":"10.1016\/j.vaccine.2021.01.071_b0120","doi-asserted-by":"crossref","first-page":"3527","DOI":"10.4049\/jimmunol.157.8.3527","article-title":"Key epitopes on the ESAT-6 antigen recognized in mice during the recall of protective immunity to Mycobacterium tuberculosis","volume":"157","author":"Brandt","year":"1996","journal-title":"J Immunol"},{"issue":"8","key":"10.1016\/j.vaccine.2021.01.071_b0125","doi-asserted-by":"crossref","first-page":"4105","DOI":"10.1128\/IAI.00004-07","article-title":"Protective immune responses to a recombinant adenovirus type 35 tuberculosis vaccine in two mouse strains: CD4 and CD8 T-cell epitope mapping and role of gamma interferon","volume":"75","author":"Radosevic","year":"2007","journal-title":"Infect Immun"},{"issue":"2","key":"10.1016\/j.vaccine.2021.01.071_b0130","doi-asserted-by":"crossref","first-page":"1018","DOI":"10.4049\/jimmunol.172.2.1018","article-title":"Development of the dendritic cell system during mouse ontogeny","volume":"172","author":"Dakic","year":"2004","journal-title":"J Immunol"},{"issue":"5","key":"10.1016\/j.vaccine.2021.01.071_b0135","doi-asserted-by":"crossref","first-page":"2219","DOI":"10.4049\/jimmunol.168.5.2219","article-title":"Efficient in vivo priming of specific cytotoxic T cell responses by neonatal dendritic cells","volume":"168","author":"Dadaglio","year":"2002","journal-title":"J Immunol"},{"issue":"7","key":"10.1016\/j.vaccine.2021.01.071_b0140","doi-asserted-by":"crossref","first-page":"933","DOI":"10.1097\/00007890-199504150-00002","article-title":"Enhanced type 2 and diminished type 1 cytokines in neonatal tolerance","volume":"59","author":"Chen","year":"1995","journal-title":"Transplantation"},{"issue":"21","key":"10.1016\/j.vaccine.2021.01.071_b0145","doi-asserted-by":"crossref","first-page":"2517","DOI":"10.1016\/j.vaccine.2012.06.020","article-title":"Oral and inactivated poliovirus vaccines in the newborn: a review","volume":"31","author":"Mateen","year":"2013","journal-title":"Vaccine"},{"issue":"3\u20134","key":"10.1016\/j.vaccine.2021.01.071_b0150","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1016\/j.vaccine.2003.07.020","article-title":"Hepatitis B immunisation induces higher antibody and memory Th2 responses in new-borns than in adults","volume":"22","author":"Ota","year":"2004","journal-title":"Vaccine"},{"issue":"11","key":"10.1016\/j.vaccine.2021.01.071_b0155","first-page":"1045","article-title":"Immunogenicity and safety of monovalent acellular pertussis vaccine at birth: a randomized clinical trial","volume":"172","author":"Wood","year":"2018","journal-title":"JAMAPediatr"},{"issue":"4","key":"10.1016\/j.vaccine.2021.01.071_b0160","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1093\/cid\/cit790","article-title":"Protection by BCG vaccine against tuberculosis: a systematic review of randomized controlled trials","volume":"58","author":"Mangtani","year":"2014","journal-title":"Clin Infect Dis"},{"issue":"5","key":"10.1016\/j.vaccine.2021.01.071_b0165","doi-asserted-by":"crossref","first-page":"1531","DOI":"10.1002\/1521-4141(200105)31:5<1531::AID-IMMU1531>3.0.CO;2-1","article-title":"Neonatal bacillus Calmette-Guerin vaccination induces adult-like IFN-gamma production by CD4+ T lymphocytes","volume":"31","author":"Vekemans","year":"2001","journal-title":"Eur J Immunol"},{"issue":"3","key":"10.1016\/j.vaccine.2021.01.071_b0170","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1046\/j.1365-2567.2002.01366.x","article-title":"Neonatal mycobacterial specific cytotoxic T-lymphocyte and cytokine profiles in response to distinct BCG vaccination strategies","volume":"105","author":"Hussey","year":"2002","journal-title":"Immunology"},{"issue":"10","key":"10.1016\/j.vaccine.2021.01.071_b0175","doi-asserted-by":"crossref","first-page":"1504","DOI":"10.1093\/cid\/civ617","article-title":"The effect of oral polio vaccine at birth on infant mortality: a randomized trial","volume":"61","author":"Lund","year":"2015","journal-title":"Clin Infect Dis"},{"issue":"6","key":"10.1016\/j.vaccine.2021.01.071_b0180","first-page":"392","article-title":"Harnessing the beneficial heterologous effects of vaccination","volume":"16","author":"Goodridge","year":"2016","journal-title":"Nat RevImmunol"},{"issue":"5","key":"10.1016\/j.vaccine.2021.01.071_b0185","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1016\/j.chom.2011.04.006","article-title":"Trained immunity: a memory for innate host defense","volume":"9","author":"Netea","year":"2011","journal-title":"Cell Host Microbe"},{"issue":"5","key":"10.1016\/j.vaccine.2021.01.071_b0190","doi-asserted-by":"crossref","first-page":"1837","DOI":"10.1172\/JCI97508","article-title":"Mycobacterial growth inhibition is associated with trained innate immunity","volume":"128","author":"Joosten","year":"2018","journal-title":"J Clin Invest"},{"issue":"542","key":"10.1016\/j.vaccine.2021.01.071_b0195","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aax4517","article-title":"BCG vaccination-induced emergency granulopoiesis provides rapid protection from neonatal sepsis","volume":"12","author":"Brook","year":"2020","journal-title":"Sci Transl Med"},{"issue":"2","key":"10.1016\/j.vaccine.2021.01.071_b0200","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1159\/000355628","article-title":"Long-lasting effects of BCG vaccination on both heterologous Th1\/Th17 responses and innate trained immunity","volume":"6","author":"Kleinnijenhuis","year":"2014","journal-title":"J Innate Immun"},{"issue":"6248","key":"10.1016\/j.vaccine.2021.01.071_b0205","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1126\/science.aaa4282","article-title":"Impairment of immunity to Candida and Mycobacterium in humans with bi-allelic RORC mutations","volume":"349","author":"Okada","year":"2015","journal-title":"Science"},{"issue":"10","key":"10.1016\/j.vaccine.2021.01.071_b0210","doi-asserted-by":"crossref","first-page":"4187","DOI":"10.1128\/IAI.01392-09","article-title":"Mycobacterium bovis BCG-specific Th17 cells confer partial protection against Mycobacterium tuberculosis infection in the absence of gamma interferon","volume":"78","author":"Wozniak","year":"2010","journal-title":"Infect Immun"},{"issue":"4","key":"10.1016\/j.vaccine.2021.01.071_b0215","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1038\/ni1449","article-title":"IL-23 and IL-17 in the establishment of protective pulmonary CD4+ T cell responses after vaccination and during Mycobacterium tuberculosis challenge","volume":"8","author":"Khader","year":"2007","journal-title":"Nat Immunol"},{"issue":"6","key":"10.1016\/j.vaccine.2021.01.071_b0220","doi-asserted-by":"crossref","first-page":"3786","DOI":"10.4049\/jimmunol.178.6.3786","article-title":"IL-17-mediated regulation of innate and acquired immune response against pulmonary Mycobacterium bovis bacille Calmette-Guerin infection","volume":"178","author":"Umemura","year":"2007","journal-title":"J Immunol"},{"issue":"2","key":"10.1016\/j.vaccine.2021.01.071_b0225","doi-asserted-by":"crossref","first-page":"300","DOI":"10.3390\/vaccines8020300","article-title":"Antigen-specific IFN-\u03b3\/IL-17-co-producing CD4(+) T-cells are the determinants for protective efficacy of tuberculosis subunit vaccine","volume":"8","author":"Choi","year":"2020","journal-title":"Vaccines (Basel)"},{"issue":"2","key":"10.1016\/j.vaccine.2021.01.071_b0230","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1002\/eji.201141569","article-title":"IL-23-dependent IL-17 drives Th1-cell responses following Mycobacterium bovis BCG vaccination","volume":"42","author":"Gopal","year":"2012","journal-title":"Eur J Immunol"},{"issue":"10","key":"10.1016\/j.vaccine.2021.01.071_b0235","doi-asserted-by":"crossref","first-page":"1221","DOI":"10.1586\/erv.12.94","article-title":"Prime-boost approaches to tuberculosis vaccine development","volume":"11","author":"Dalmia","year":"2012","journal-title":"Expert Rev Vaccines"},{"issue":"2","key":"10.1016\/j.vaccine.2021.01.071_b0240","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1038\/nm.4473","article-title":"Prevention of tuberculosis in rhesus macaques by a cytomegalovirus-based vaccine","volume":"24","author":"Hansen","year":"2018","journal-title":"Nat Med"},{"key":"10.1016\/j.vaccine.2021.01.071_b0245","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1038\/s41541-019-0113-9","article-title":"Boosting BCG with proteins or rAd5 does not enhance protection against tuberculosis in rhesus macaques","volume":"4","author":"Darrah","year":"2019","journal-title":"npj Vaccines"},{"issue":"7788","key":"10.1016\/j.vaccine.2021.01.071_b0250","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1038\/s41586-019-1817-8","article-title":"Prevention of tuberculosis in macaques after intravenous BCG immunization","volume":"577","author":"Darrah","year":"2020","journal-title":"Nature"}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X21001122?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X21001122?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,2]],"date-time":"2025-10-02T10:53:37Z","timestamp":1759402417000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X21001122"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,3]]},"references-count":50,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2021,3]]}},"alternative-id":["S0264410X21001122"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2021.01.071","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2021,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Intranasal boosting with MVA encoding secreted mycobacterial proteins Ag85A and ESAT-6 generates strong pulmonary immune responses and protection against M. tuberculosis in mice given BCG as neonates","name":"articletitle","label":"Article Title"},{"value":"Vaccine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vaccine.2021.01.071","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}